Skip to Main Content
Contribute Try STAT+ Today

After months of planning, the Louisiana Department of Health has chosen a new Gilead Sciences (GILD) subsidiary to supply a hepatitis C medicine under a so-called Netflix payment model.

The deal revolves around subscription-based payments. Asegua Therapeutics, the Gilead unit, has agreed to provide the state Medicaid program and Department of Corrections with unlimited access to an authorized generic version of the Epclusa treatment for a fixed amount of money for five years, according to the state Department of Health. A contract is expected to be finalized by June 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.